# Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation

> **NCT04858958** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 30 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Furmonertinib 160mg
- **DRUG:** Furmonertinib 240mg

## Key facts

- **NCT ID:** NCT04858958
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-10
- **Primary completion:** 2024-12-05
- **Final completion:** 2026-02-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04858958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04858958, "Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04858958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*